ASX Share rice
Thu 13 Aug 2020 - 03:34:am (Sydney)

ACW Share Price

ACTINOGEN MEDICAL LIMITEDACWPharmaceuticals, Biotechnology & Life Sciences

ACW Company Information

Name:

Actinogen Medical Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

109 Pitt Street Sydney NSW Australia 2000

Phone:

61 2 8964 7401

MD, CEO & Director:

Dr. John William Ketelbey MBBCH, FFPM, MBA, GAICD

Company Sec.:

Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD

Company Overview:

Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer's disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia. It is developing Xanamem, a therapy for Alzheimer's disease; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. The company is also developing XanaHES, a Phase I, single blinded, central reader blinded, placebo-controlled, dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited is based in Sydney, Australia.

ACW Share Price Information

Shares Issued:

1.12B

Market Capitalisation:

$26.79M

Revenue (TTM):

$5.73M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.009

Profit Margin:

-1.1867

Operating Margin (TTM):

$-1.10

Return On Assets (TTM):

$-0.24

Return On Equity (TTM):

$-0.45

Quarterly Revenue Growth (YOY):

8.258

Gross Profit(TTM):

$5.07M

Diluted Earnings Per Share (TTM):

$-0.006

ACW CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$71.77K

Change To Liabilities:

$-215,650

Total Cashflow From Investing Activities:

$71.77K

Net Borrowings:

$560K

Net Income:

$-9,887,682

Total Cash From Operating Activities:

$-10,498,298

Depreciation:

$353.50K

Other Cashflow From Investing Activities:

$71.77K

Change To Account Receivables:

$-1,358,107

Capital Expenditures:

$0

ACW Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-9,887,682

Net Income:

$-9,887,682

Gross Profit:

$80.82K

Operating Income:

$-14,470,096

Interest Expense:

$7.99K

Total Revenue:

$80.82K

Total Operating Expenses:

$14.47M

ACW Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$3.66M

Total Liabilities:

$557.40K

Total Stockholder Equity:

$15.66M

Other Current Liabilities:

$183.11K

Total Assets:

$16.22M

Common Stock:

$51.44M

Retained Earnings:

$-39,196,317

Other Assets:

$35.27K

Cash:

$7.64M

Total Current Liabilities:

$557.40K

Net Tangible Assets:

$12M

Total Current Assets:

$12.53M

Net Receivables:

$4.83M

Short-Term Investments:

$3.69M

Accounts Payable:

$282.82K

Non Currrent Assets (Other):

$3.69M

Short-Term Investments:

$3.69

Non Current Liabilities Total:

$0

ACW Share Price History

ACW News

15 Apr, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
17 Dec, 2019
Actinogen Medical Limited (ASX:ACW) shareholders will doubtless be very grateful to see the share price up 350% in the...
18 Oct, 2019
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
01 Oct, 2019
SYDNEY-- -- Statistically significant results demonstrate cognitive improvement in healthy elderly subjects dosed with 20mg Xanamem daily in the XanaHES dose escalation study Statistically significant reduction in serum cortisol following treatment with Xanamem 20mg daily Xanamem 20mg daily continues to exhibit a good safety profile with no serious adverse events observed Results significantly enhance ...
12 Sep, 2019
The big shareholder groups in Actinogen Medical Limited (ASX:ACW) have power over the company. Institutions will often...